The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | First-in-human study of modakafusp alfa for the treatment of R/R multiple myeloma
Dan Vogl, MD, University of Pennsylvania, Philadelphia, PA, shares some
results from the Phase I/II first-in-human study of modakafusp alfa for the treatment of relapsed/refractory (R/R) multiple myeloma (MM). Dr Vogl first explains the mechanism of action of this agent, and then goes on to highlight some findings from this study, including the overall response rate (ORR) and side effect profile observed. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Consultancy; Sanofi/Genzyme: Consultancy; CSL/Behring: Consultancy; Karyopharm: Consultancy; Oncopeptides: Consultancy; Active Biotech: Research Funding; Takeda: Consultancy, Research Funding.
